PRTK - パラテック・ファ―マシュ―ティカルズ (Paratek Pharmaceuticals Inc. )

PRTKのニュース

   Insider Selling: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Insider Sells 4,479 Shares of Stock  2021/12/18 13:02:42 Transcript Daily
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 4,479 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $4.42, for a total transaction of $19,797.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which []
   Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel Sells $21,551.92 in Stock  2021/12/18 13:02:42 Dakota Financial News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,876 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $4.42, for a total transaction of $21,551.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []
   William M. Haskel Sells 17,178 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock  2021/12/17 13:42:46 Transcript Daily
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 17,178 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $73,350.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []
   Randall B. Brenner Sells 15,780 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock  2021/12/17 13:42:45 Dakota Financial News
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) insider Randall B. Brenner sold 15,780 shares of the firms stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $4.27, for a total value of $67,380.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. []
   Head-To-Head Comparison: Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA)  2021/11/27 13:48:42 Dakota Financial News
Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Paratek Pharmaceuticals has a beta of 1.5, suggesting that its stock price is []
   Head-To-Head Comparison: Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA)  2021/11/27 13:48:42 Dakota Financial News
Paratek Pharmaceuticals (NASDAQ:PRTK) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Paratek Pharmaceuticals has a beta of 1.5, suggesting that its stock price is []
   Northern Trust Corp Sells 5,228 Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)  2021/11/23 09:18:42 Transcript Daily
Northern Trust Corp lowered its holdings in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 1.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 481,062 shares of the specialty pharmaceutical companys stock after selling 5,228 shares during the period. Northern Trust Corp owned approximately 0.99% of []
   Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Expected to Post Quarterly Sales of $33.52 Million  2021/11/15 21:12:43 Transcript Daily
Equities research analysts expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to report $33.52 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Paratek Pharmaceuticals earnings, with the lowest sales estimate coming in at $31.64 million and the highest estimate coming in at $35.39 million. Paratek Pharmaceuticals reported sales of $16.02 million []
   Paratek Pharmaceuticals (NASDAQ:PRTK) Given New $27.00 Price Target at HC Wainwright  2021/11/10 10:34:44 Transcript Daily
Paratek Pharmaceuticals (NASDAQ:PRTK) had its price target lowered by HC Wainwright from $28.00 to $27.00 in a research note published on Tuesday, Analyst Ratings Network reports. The brokerage currently has a buy rating on the specialty pharmaceutical companys stock. Separately, Zacks Investment Research raised shares of Paratek Pharmaceuticals from a sell rating to a hold []
   Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2021 Results - Earnings Call Transcript  2021/11/09 01:44:02 Seeking Alpha
   Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/09 12:30:00 Intrado Digital Media
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Randy Brenner, Chief Development and Regulatory Officer, will present at the H.C. Wainwright 23 rd Annual Global Investment (Virtual) Conference. The on-demand presentation will be available on September 13 at 7:00 a.m. ET.
   Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria  2021/08/18 20:12:00 Intrado Digital Media
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for NUZYRA ® (omadacycline) for the treatment of infections caused by Nontuberculous Mycobacteria (NTM). This orphan drug designation includes NTM pulmonary disease caused by Mycobacterium abscessus complex (MABc), which is the focus of an ongoing Phase 2b study initiated by Paratek. The FDAs Office of Orphan Drug Products grants orphan status to drugs and biologics that demonstrate promise for the treatment of diseases or conditions affecting fewer than 200,000 people in the United States. Orphan drug designation provides Paratek with certain development incentives, including tax credits for qualified clinical testing, exemptions from certain FDA application fees, and potential market exclusivity, if approved. The orphan drug designation is an important regulatory milestone that further validates our efforts to investigate the utility of NUZYRA, a once-daily, broad-spectrum antibiotic currently approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, as a potential therapy option for patients afflicted with M. abscessus pulmonary disease, an orphan disease for which there are no approved therapies, said Randy Brenner, Chief Development and Regulatory Officer of Paratek. Earlier this year, we initiated our Phase 2b clinical study that is designed to examine the efficacy and safety of NUZYRA in patients with M. abscessus pulmonary disease.
   Paratek Pharmaceuticals (PRTK) Investor Presentation - Slideshow  2021/08/13 20:29:00 Seeking Alpha
   Paratek Pharmaceuticals EPS misses by $0.12, misses on revenue  2021/08/09 20:25:29 Seeking Alpha
   Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021  2021/08/09 20:05:00 Intrado Digital Media
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter

calendar